Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China

INTRODUCTION: Tyrosine-kinase inhibitors (TKIs) have become the standard treatment for patients with advanced gastrointestinal stromal tumor (GIST); however, secondary mutations can still drive disease progression. Studies have shown that ripretinib, a novel switch-control TKI, inhibits various prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinhua, Zhang, Peng, Qiu, Haibo, Fang, Yong, Liu, Heli, Zhou, Yongjian, Xu, Hao, Yu, JiRen, Zhang, Jun, Wang, Ming, Shen, Lin, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427548/
https://www.ncbi.nlm.nih.gov/pubmed/37356078
http://dx.doi.org/10.1007/s12325-023-02576-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427548/
https://www.ncbi.nlm.nih.gov/pubmed/37356078
http://dx.doi.org/10.1007/s12325-023-02576-0

Ejemplares similares